GB0903759D0 - Compound - Google Patents

Compound

Info

Publication number
GB0903759D0
GB0903759D0 GBGB0903759.9A GB0903759A GB0903759D0 GB 0903759 D0 GB0903759 D0 GB 0903759D0 GB 0903759 A GB0903759 A GB 0903759A GB 0903759 D0 GB0903759 D0 GB 0903759D0
Authority
GB
United Kingdom
Prior art keywords
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0903759.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB0903759.9A priority Critical patent/GB0903759D0/en
Publication of GB0903759D0 publication Critical patent/GB0903759D0/en
Priority to CN2010800108001A priority patent/CN102341400A/zh
Priority to JP2011552507A priority patent/JP2012519678A/ja
Priority to PCT/GB2010/000394 priority patent/WO2010100431A1/en
Priority to AU2010219466A priority patent/AU2010219466A1/en
Priority to US13/254,355 priority patent/US20120088753A1/en
Priority to EP10707338.9A priority patent/EP2403853B1/en
Priority to CA2753236A priority patent/CA2753236A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0903759.9A 2009-03-04 2009-03-04 Compound Ceased GB0903759D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0903759.9A GB0903759D0 (en) 2009-03-04 2009-03-04 Compound
CN2010800108001A CN102341400A (zh) 2009-03-04 2010-03-04 用作激酶抑制剂的吡咯并嘧啶化合物
JP2011552507A JP2012519678A (ja) 2009-03-04 2010-03-04 キナーゼ阻害剤として使用されるピロロピリミジン
PCT/GB2010/000394 WO2010100431A1 (en) 2009-03-04 2010-03-04 Pyrrolopyrimidines used as kinase inhibitors
AU2010219466A AU2010219466A1 (en) 2009-03-04 2010-03-04 Pyrrolopyrimidines used as kinase inhibitors
US13/254,355 US20120088753A1 (en) 2009-03-04 2010-03-04 Pyrrolopyrimidines and used as kinase inhibitors
EP10707338.9A EP2403853B1 (en) 2009-03-04 2010-03-04 Pyrrolopyrimidines used as kinase inhibitors
CA2753236A CA2753236A1 (en) 2009-03-04 2010-03-04 Pyrrolopyrimidines used as kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0903759.9A GB0903759D0 (en) 2009-03-04 2009-03-04 Compound

Publications (1)

Publication Number Publication Date
GB0903759D0 true GB0903759D0 (en) 2009-04-15

Family

ID=40580647

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0903759.9A Ceased GB0903759D0 (en) 2009-03-04 2009-03-04 Compound

Country Status (8)

Country Link
US (1) US20120088753A1 (enExample)
EP (1) EP2403853B1 (enExample)
JP (1) JP2012519678A (enExample)
CN (1) CN102341400A (enExample)
AU (1) AU2010219466A1 (enExample)
CA (1) CA2753236A1 (enExample)
GB (1) GB0903759D0 (enExample)
WO (1) WO2010100431A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
PL2714668T3 (pl) * 2011-05-23 2017-06-30 Merck Patent Gmbh Pochodne tiazolowe
LT2714677T (lt) * 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
KR20140063700A (ko) 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
CN104093722B (zh) * 2012-02-09 2016-07-27 默克专利股份公司 作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
SG11201701724VA (en) 2014-09-26 2017-04-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
KR101660863B1 (ko) 2015-04-03 2016-09-28 주식회사 녹십자 IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
KR101846475B1 (ko) 2015-04-27 2018-04-09 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
BR112017002594A2 (pt) 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
CN111788183B (zh) 2018-02-07 2024-02-23 韩国化学硏究院 用于抑制tnik的杂环融合苯基化合物及其医疗用途
JP7302794B2 (ja) 2018-02-07 2023-07-04 コリア リサーチ インスティチュート オブ ケミカル テクノロジー Ｔｎｉｋを阻害するための化合物及びその医学的使用
CN112225742B (zh) * 2020-12-11 2021-03-09 北京华氏开元医药科技有限公司 一种抑制vegfr活性的化合物、制备方法及应用
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
PL1713806T3 (pl) 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
CN101252935A (zh) 2005-08-24 2008-08-27 莱西肯医药有限公司 吡咯并吡啶，吡咯并嘧啶和吡唑并吡啶化合物，包含它们的组合物及它们的使用方法
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途

Also Published As

Publication number Publication date
EP2403853B1 (en) 2013-08-14
WO2010100431A1 (en) 2010-09-10
EP2403853A1 (en) 2012-01-11
US20120088753A1 (en) 2012-04-12
AU2010219466A1 (en) 2011-09-01
CA2753236A1 (en) 2010-09-10
CN102341400A (zh) 2012-02-01
JP2012519678A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
EP2423182A4 (en) DIACYLETHYLENDIAMINVERBINDUNG
GB0907425D0 (en) Compounds
EP2393493A4 (en) LINKS
IL219248A0 (en) Compounds
GB0907515D0 (en) Compounds
GB0914767D0 (en) Compound
GB0905641D0 (en) Compounds
GB0909671D0 (en) Compounds
GB0909213D0 (en) Compound
EP2487178A4 (en) PYRAZOLOTHIAZOLVERBINDUNG
GB0909672D0 (en) Compounds
AP2909A (en) Pyrazinoisoquinoline Compounds
GB0914883D0 (en) Compound
EP2443115A4 (en) COMPOUNDS
GB0906821D0 (en) Compound
GB0922714D0 (en) Compound
GB0922003D0 (en) Compound
GB0916603D0 (en) Compound
GB0910692D0 (en) Compound
GB0917460D0 (en) Compound
GB0901976D0 (en) Compound
GB0907825D0 (en) Novel compound
GB0905060D0 (en) Compounds
GB0905054D0 (en) Compounds
GB0904729D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)